Amarantus Biosciences Holdings, Inc. (OTCBB:AMBS) Tries to Generate Hype

Amarantus Biosciences Holdings, inc. (OTCBB:AMBS)’s stock is going through a tough period and can’t seem to find out in what direction it is heading. It can’t be any other way, considering that the ticker’s price is mainly relying on press releases and there are no significant developments.

The latest press release is centered on AMBS‘s CEO and President, Gerald Commissiong attending the 2013 Aegis Healthcare Conference where the company will be presented alongside other biothech companies, including ones that we are familiar with from the OTC Markets, like Invivo Therapeutics Holdings Corp. (OTCBB:NVIV) and AtheroNova, Inc. (OTCMKTS:AHRO).

The hype generated from these news was short lived and the ticker registered a 16% gain on September 24, with a decent amount of traded shares that generated $386 thousand in dollar volume for the day.

Things didn’t last long, however, as they lost 10% the very next day and closed yesterday’s session priced at $0.063. The total amount of shares that switched hands came at 7.1 million and registered an estimated $470 thousand in trade value.

As we mentioned in our previous article the strong side of AMBS is the huge Twitter follower base that surpasses 8000 people, who are regularly touting them, attracting new investors to the company. Things, however, have been going slow for AMBS with their projects and the hopes of a big investor and a revolutionary drug aren’t enough to keep them headed in the desired direction.

All in all AMBS is one of the riskiest stocks out there so it might fit you if you are looking for a speculative play. Any other decisions would be irrational, as they would contain a great amount of risk.